|
Your search returned 250 studies:
- "Touch 2 Screen" Multi-media Colorectal Cancer Screening Intervention - NCT00594113-66160
Conditions: Colorectal Cancer
Location: Kansas City, KS
- [18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors - NCT00832598-10065
Conditions: Brain Cancer - Gliomas
Location: New York, NY
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer - NCT00588185-10065
Conditions: Prostate Cancer
Location: New York, NY
- [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors - NCT00707343-84112
Conditions: Cancer - Brain Tumors
Location: Salt Lake City, UT
- [F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer - NCT00282906-90033
Conditions: Prostate Cancer
Location: Los Angeles, CA
- 124I-FIAU Imaging in EBV and KSHV Associated Cancers - NCT00982449-21287
Conditions: Hodgkin Lymphoma - Non Hodgkin Lymphoma - Kaposi's Sarcoma - Gastric Cancer - Nasopharyngeal Cancer
Location: Baltimore, MD
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer - NCT00859781-10021
Conditions: Prostate Cancer
Location: New York, NY
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors - NCT00967577-10021
Conditions: Kidney Cancer - Head and Neck Cancer - Breast Cancer - Non-small Cell Lung Cancer - Colorectal Cancer - Pancreatic Cancer - Ovarian Cancer - Esophageal Cancer - Gliomas
Location: New York, NY
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-01107
Conditions: Breast Cancer
Location: Springfield, MA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-02118
Conditions: Breast Cancer
Location: Boston, MA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-04474
Conditions: Breast Cancer
Location: Scarborough, ME
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-06611
Conditions: Breast Cancer
Location: Trumbull, CT
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-06902
Conditions: Breast Cancer
Location: Stamford, CT
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-07134
Conditions: Breast Cancer
Location: Denville, NJ
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-10065
Conditions: Breast Cancer
Location: New York, NY
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-11432
Conditions: Breast Cancer
Location: Jamaica, NY
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-13057
Conditions: Breast Cancer
Location: East Syracuse, NY
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-14263
Conditions: Breast Cancer
Location: Buffalo, NY
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-18512
Conditions: Breast Cancer
Location: Dunmore, PA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-19106
Conditions: Breast Cancer
Location: Philadelphia, PA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-20007
Conditions: Breast Cancer
Location: Washington, DC
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-20010
Conditions: Breast Cancer
Location: Washington, DC
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-28204
Conditions: Breast Cancer
Location: Charlotte, NC
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-29403
Conditions: Breast Cancer
Location: Charleston, SC
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-30060
Conditions: Breast Cancer
Location: Marietta, GA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-30901
Conditions: Breast Cancer
Location: Augusta, GA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-31201A
Conditions: Breast Cancer
Location: Macon, GA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-31201B
Conditions: Breast Cancer
Location: Macon, GA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-34613
Conditions: Breast Cancer
Location: Brooksville, FL
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-34652
Conditions: Breast Cancer
Location: New Port Richey, FL
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-38120
Conditions: Breast Cancer
Location: Memphis, TN
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-44870
Conditions: Breast Cancer
Location: Sandusky, OH
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-46601
Conditions: Breast Cancer
Location: South Bend, IN
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-48105
Conditions: Breast Cancer
Location: Ann Arbor, MI
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-53212
Conditions: Breast Cancer
Location: Glendale, WI
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-60426
Conditions: Breast Cancer
Location: Harvey, IL
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-60611
Conditions: Breast Cancer
Location: Chicago, IL
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-60612
Conditions: Breast Cancer
Location: Chicago, IL
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-62301
Conditions: Breast Cancer
Location: Quincy, IL
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-65109
Conditions: Breast Cancer
Location: Jefferson City, MO
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-70809
Conditions: Breast Cancer
Location: Baton Rouge, LA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-72703
Conditions: Breast Cancer
Location: Fayetteville, AR
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-80528
Conditions: Breast Cancer
Location: Fort Collins, CO
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-90806
Conditions: Breast Cancer
Location: Long Beach, CA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-92501
Conditions: Breast Cancer
Location: Riverside, CA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-92879A
Conditions: Breast Cancer
Location: Corona, CA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-92879B
Conditions: Breast Cancer
Location: Fountain Valley, CA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-94107
Conditions: Breast Cancer
Location: San Francisco, CA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-94115
Conditions: Breast Cancer
Location: San Francisco, CA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-94904
Conditions: Breast Cancer
Location: Greenbrae, CA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-98516
Conditions: Breast Cancer
Location: Sacramento, CA
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy - NCT00493636-99508
Conditions: Breast Cancer
Location: Anchorage, AK
- 3 Tesla MRI in Patients With Bladder Cancer - NCT00938145-43210
Conditions: Bladder Cancer
Location: Columbus, OH
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma - NCT00293345-43210
Conditions: Lymphoma - Small Intestine Cancer - Unspecified Adult Solid Tumor, Protocol Specific
Location: Columbus, OH
- 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery - NCT00288093-43210
Conditions: Pancreatic Cancer
Location: Columbus, OH
- 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx - NCT00757549-55905
Conditions: Head and Neck Cancer
Location: Rochester, MN
- 3'-Deoxy-3'-[18F] Fluorothymidine PET/CT Scanning in Patients Undergoing Treatment for Stage III Breast Cancer - NCT00566293-20892
Conditions: Breast Cancer
Location: Bethesda, MD
- 3'-Deoxy-3'-[18F] Fluorothymidine PET/CT Scanning in Patients Undergoing Treatment for Stage III Breast Cancer - NCT00566293-23298
Conditions: Breast Cancer
Location: Richmond, VA
- 3-Dimensional Conformal Radiation Therapy, Arterial Embolization, and Tumor Cell Vaccine in Treating Patients With Unresectable, Recurrent, or Metastatic Primary Liver Cancer or Pancreatic Cancer - NCT00553683-07101
Conditions: Liver Cancer - Pancreatic Cancer
Location: Newark, NJ
- 3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate - NCT00429338-77030
Conditions: Prostate Cancer
Location: Houston, TX
- 3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate - NCT00464724-77030
Conditions: Prostate Cancer
Location: Houston, TX
- 4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis - NCT00862680-77030
Conditions: Colorectal Cancer - Lung Cancer - Liver Cancer
Location: Houston, TX
- 4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic Malignancies - NCT00531180-77030
Conditions: Esophageal Cancer - Lung Cancer
Location: Houston, TX
- 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ - NCT00952731-27704
Conditions: Breast Cancer
Location: Durham, NC
- 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ - NCT00952731-60611
Conditions: Breast Cancer
Location: Chicago, IL
- 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ - NCT00952731-63110
Conditions: Breast Cancer
Location: Saint Louis, MO
- 5-Aza-2-Deoxycitidine With Pegylated Interferon-Alfa 2B: A Phase I Study With Molecular Correlates - NCT00886457-89135
Conditions: Cancer
Location: Las Vegas, NV
- 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors - NCT00378807-20892
Conditions: Breast Cancer - Unspecified Adult Solid Tumor, Protocol Specific
Location: Bethesda, MD
- 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors - NCT00378807-90089
Conditions: Breast Cancer - Unspecified Adult Solid Tumor, Protocol Specific
Location: Los Angeles, CA
- 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors - NCT00378807-91010
Conditions: Breast Cancer - Unspecified Adult Solid Tumor, Protocol Specific
Location: Duarte, CA
- 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors - NCT00378807-95817
Conditions: Breast Cancer - Unspecified Adult Solid Tumor, Protocol Specific
Location: Sacramento, CA
- 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 or Lapatinib or Trastuzumab - NCT00826267-
Conditions: Breast Neoplasms
Location: Houston, TX
- 64CuATSM and Hypoxia in Stage IIIB/IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab - NCT01006226-63110
Conditions: Carcinoma, Non-Small-Cell Lung
Location: St. Louis, MO
- A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer - NCT00918008-10065A
Conditions: Bladder Cancer
Location: New York, NY
- A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer - NCT00918008-10065B
Conditions: Bladder Cancer
Location: New York, NY
- A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC. - NCT00863746-72764
Conditions: Carcinoma, Non-Small-Cell Lung
Location: Springdale, AR
- A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC. - NCT00863746-92708
Conditions: Carcinoma, Non-Small-Cell Lung
Location: Fountain Valley, CA
- A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC. - NCT00863746-94305
Conditions: Carcinoma, Non-Small-Cell Lung
Location: Stanford, CA
- A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer - NCT00666731-68198
Conditions: Breast Cancer - Precancerous Condition
Location: Omaha, NE
- A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer - NCT00666731-68803
Conditions: Breast Cancer - Precancerous Condition
Location: Grand Island, NE
- A Clinical Study of PHY906 as a Modulator of CPT-11 in Patients With Metastatic Colorectal Cancer - NCT00730158-06516
Conditions: Colorectal Neoplasms
Location: West Haven, CT
- A Clinical Study of PHY906 as a Modulator of CPT-11 in Patients With Metastatic Colorectal Cancer - NCT00730158-06520
Conditions: Colorectal Neoplasms
Location: New Haven, CT
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-20037
Conditions: Breast Cancer
Location: Washington, DC
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-33140
Conditions: Breast Cancer
Location: Miami Beach, FL
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-33486
Conditions: Breast Cancer
Location: Boca Raton, FL
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-33919
Conditions: Breast Cancer
Location: Fort Myers, FL
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-61615
Conditions: Breast Cancer
Location: Peoria, IL
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-66160
Conditions: Breast Cancer
Location: Kansas City, KS
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-70508
Conditions: Breast Cancer
Location: Lafayette, LA
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-75390
Conditions: Breast Cancer
Location: Dallas, TX
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-92201
Conditions: Breast Cancer
Location: Indio, CA
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-93942
Conditions: Breast Cancer
Location: Monterey, CA
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-95403
Conditions: Breast Cancer
Location: Santa Rosa, CA
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. - NCT00816530-98111
Conditions: Breast Cancer
Location: Seattle, WA
- A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies - NCT00983619-20007
Conditions: Cancer
Location: Washington, DC
- A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies - NCT00983619-33612
Conditions: Cancer
Location: Tampa, FL
- A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer - NCT00907959-77030
Conditions: Metastatic Breast Cancer
Location: Houston, TX
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-10021
Conditions: Kidney Neoplasms
Location: New York, NY
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-10022
Conditions: Kidney Neoplasms
Location: New York, NY
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-27710
Conditions: Kidney Neoplasms
Location: Durham, NC
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-70002
Conditions: Kidney Neoplasms
Location: Metairie, LA
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-70006
Conditions: Kidney Neoplasms
Location: Metairie, LA
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-70072
Conditions: Kidney Neoplasms
Location: Marrero, LA
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-70115
Conditions: Kidney Neoplasms
Location: New Orleans, LA
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-70433
Conditions: Kidney Neoplasms
Location: Covington, LA
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-84103
Conditions: Kidney Neoplasms
Location: Salt Lake City, UT
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-84107
Conditions: Kidney Neoplasms
Location: Murray, UT
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-85258
Conditions: Kidney Neoplasms
Location: Scottsdale, AZ
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer - NCT00375674-90095
Conditions: Kidney Neoplasms
Location: Los Angeles, CA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-01201
Conditions: Breast Cancer
Location: Pittsfield, MA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-04401
Conditions: Breast Cancer
Location: Bangor, ME
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-05201
Conditions: Breast Cancer
Location: Bennington, VT
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-06032
Conditions: Breast Cancer
Location: Farmington, CT
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-07054
Conditions: Breast Cancer
Location: Parsippany, NJ
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-07112
Conditions: Breast Cancer
Location: Newark, NJ
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-07960
Conditions: Breast Cancer
Location: Morristown, NJ
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-08876
Conditions: Breast Cancer
Location: Somerville, NJ
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-11030
Conditions: Breast Cancer
Location: Manhasset, NY
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-11040
Conditions: Breast Cancer
Location: New Hyde Park, NY
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-11794
Conditions: Breast Cancer
Location: Stonybrook, NY
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-12801
Conditions: Breast Cancer
Location: Glens Falls, NY
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-14420
Conditions: Breast Cancer
Location: Brockport, NY
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-14424
Conditions: Breast Cancer
Location: Canandaigua, NY
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-14456
Conditions: Breast Cancer
Location: Geneva, NY
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-14623
Conditions: Breast Cancer
Location: Rochester, NY
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-14626
Conditions: Breast Cancer
Location: Rochester, NY
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-15212
Conditions: Breast Cancer
Location: Pittsburgh, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-15232
Conditions: Breast Cancer
Location: Pittsburgh, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-16801
Conditions: Breast Cancer
Location: State College, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-17522
Conditions: Breast Cancer
Location: Ephrata, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-17882
Conditions: Breast Cancer
Location: Danville, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-18201
Conditions: Breast Cancer
Location: Hazleton, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-18301
Conditions: Breast Cancer
Location: E. Stroudsburg, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-18501
Conditions: Breast Cancer
Location: Scranton, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-18510
Conditions: Breast Cancer
Location: Scranton, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-18704
Conditions: Breast Cancer
Location: Kingston, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-18711
Conditions: Breast Cancer
Location: Wilkes-Barre, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-19013
Conditions: Breast Cancer
Location: Upland, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-19107A
Conditions: Breast Cancer
Location: Philadelphia, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-19107B
Conditions: Breast Cancer
Location: Philadelphia, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-19141
Conditions: Breast Cancer
Location: Philadelphia, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-19611
Conditions: Breast Cancer
Location: West Reading, PA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-20010
Conditions: Breast Cancer
Location: Washington, DC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-20016
Conditions: Breast Cancer
Location: Washington, DC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-20155
Conditions: Breast Cancer
Location: Gainesville, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-20176
Conditions: Breast Cancer
Location: Leesburg, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-20815
Conditions: Breast Cancer
Location: Chevy Chase, MD
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-20817
Conditions: Breast Cancer
Location: Bethesda, MD
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-21044
Conditions: Breast Cancer
Location: Columbia, MD
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-21117
Conditions: Breast Cancer
Location: Owings Mills, MD
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-21157
Conditions: Breast Cancer
Location: Westminster, MD
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-21202
Conditions: Breast Cancer
Location: Baltimore, MD
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-21204A
Conditions: Breast Cancer
Location: Baltimore, MD
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-21204B
Conditions: Breast Cancer
Location: Baltimore, MD
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-21237
Conditions: Breast Cancer
Location: Baltimore, MD
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-21701
Conditions: Breast Cancer
Location: Frederick, MD
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-22031
Conditions: Breast Cancer
Location: Fairfax, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-22033
Conditions: Breast Cancer
Location: Fairfax, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-22191
Conditions: Breast Cancer
Location: Woodbridge, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-22205
Conditions: Breast Cancer
Location: Arlington, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-22601
Conditions: Breast Cancer
Location: Winchester, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23114
Conditions: Breast Cancer
Location: Midlothian, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23116
Conditions: Breast Cancer
Location: Mechanicsville, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23188
Conditions: Breast Cancer
Location: Williamsburg, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23226
Conditions: Breast Cancer
Location: Richmond, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23235
Conditions: Breast Cancer
Location: Richmond, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23298
Conditions: Breast Cancer
Location: Richmond, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23320
Conditions: Breast Cancer
Location: Chesapeake, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23456
Conditions: Breast Cancer
Location: Virginia Beach, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23502
Conditions: Breast Cancer
Location: Norfolk, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23606A
Conditions: Breast Cancer
Location: Hampton, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-23606B
Conditions: Breast Cancer
Location: Newport News, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-24014
Conditions: Breast Cancer
Location: Roanoke, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-24073
Conditions: Breast Cancer
Location: Christiansburg, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-24153
Conditions: Breast Cancer
Location: Salem, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-24382
Conditions: Breast Cancer
Location: Wytheville, VA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-25304
Conditions: Breast Cancer
Location: Charleston, WV
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-25801
Conditions: Breast Cancer
Location: Beckley, WV
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-26003
Conditions: Breast Cancer
Location: Wheeling, WV
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-26101
Conditions: Breast Cancer
Location: Parkersburg, WV
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-26506
Conditions: Breast Cancer
Location: Morgantown, WV
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-27103
Conditions: Breast Cancer
Location: Winston-Salem, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-27217
Conditions: Breast Cancer
Location: Burlington, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-27518
Conditions: Breast Cancer
Location: Cary, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-27534
Conditions: Breast Cancer
Location: Goldsboro, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-27607
Conditions: Breast Cancer
Location: Raleigh, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-27614
Conditions: Breast Cancer
Location: Raleigh, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-27704
Conditions: Breast Cancer
Location: Durham, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-27834
Conditions: Breast Cancer
Location: Greenville, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-27909
Conditions: Breast Cancer
Location: Elizabeth City, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-28232
Conditions: Breast Cancer
Location: Charlotte, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-28233
Conditions: Breast Cancer
Location: Charlotte, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-28302
Conditions: Breast Cancer
Location: Fayetteville, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-28791
Conditions: Breast Cancer
Location: Hendersonville, NC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-29210
Conditions: Breast Cancer
Location: Columbia, SC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-29307
Conditions: Breast Cancer
Location: Spartanburg, SC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-29401
Conditions: Breast Cancer
Location: Charleston, SC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-29425
Conditions: Breast Cancer
Location: Charleston, SC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-29605A
Conditions: Breast Cancer
Location: Greenville, SC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-29605B
Conditions: Breast Cancer
Location: Greenville, SC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-29615
Conditions: Breast Cancer
Location: Greenville, SC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-29640
Conditions: Breast Cancer
Location: Easley, SC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-29672
Conditions: Breast Cancer
Location: Seneca, SC
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-30045
Conditions: Breast Cancer
Location: Lawrenceville, GA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-30736
Conditions: Breast Cancer
Location: Ringgold, GA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-31021
Conditions: Breast Cancer
Location: Dublin, GA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-31404
Conditions: Breast Cancer
Location: Savannah, GA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-31703
Conditions: Breast Cancer
Location: Albany, GA
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-32159
Conditions: Breast Cancer
Location: Lady Lake, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-32207A
Conditions: Breast Cancer
Location: Jacksonville, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-32207B
Conditions: Breast Cancer
Location: Jacksonville, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-32789
Conditions: Breast Cancer
Location: Winter Park, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-32806
Conditions: Breast Cancer
Location: Orlando, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-32901
Conditions: Breast Cancer
Location: Melbourne, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33133
Conditions: Breast Cancer
Location: Miami, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33140
Conditions: Breast Cancer
Location: Miami Beach, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33143
Conditions: Breast Cancer
Location: Miami, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33176A
Conditions: Breast Cancer
Location: Miami, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33176B
Conditions: Breast Cancer
Location: Miami, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33308
Conditions: Breast Cancer
Location: Fort Lauderdale, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33607
Conditions: Breast Cancer
Location: Tampa, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33756
Conditions: Breast Cancer
Location: Clearwater, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33908A
Conditions: Breast Cancer
Location: Fort Myers, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33908B
Conditions: Breast Cancer
Location: Fort Myers, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33914
Conditions: Breast Cancer
Location: Cape Coral, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33916
Conditions: Breast Cancer
Location: Fort Myers, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33980
Conditions: Breast Cancer
Location: Port Charlotte, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33990A
Conditions: Breast Cancer
Location: Cape Coral, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-33990B
Conditions: Breast Cancer
Location: Englewood, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34102
Conditions: Breast Cancer
Location: Naples, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34119
Conditions: Breast Cancer
Location: Naples, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34135
Conditions: Breast Cancer
Location: Bonita Springs, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34209
Conditions: Breast Cancer
Location: Bradenton, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34232
Conditions: Breast Cancer
Location: Sarasota, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34236
Conditions: Breast Cancer
Location: Sarasota, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34285
Conditions: Breast Cancer
Location: Venice, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34292
Conditions: Breast Cancer
Location: Venice, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34478
Conditions: Breast Cancer
Location: Ocala, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34655
Conditions: Breast Cancer
Location: New Port Richey, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34667
Conditions: Breast Cancer
Location: Hudson, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-34761
Conditions: Breast Cancer
Location: Ocoee, FL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-35022
Conditions: Breast Cancer
Location: Bessemer, AL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-35205
Conditions: Breast Cancer
Location: Birmingham, AL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-35209
Conditions: Breast Cancer
Location: Birmingham, AL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-35211
Conditions: Breast Cancer
Location: Birmingham, AL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-35213
Conditions: Breast Cancer
Location: Birmingham, AL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-35235
Conditions: Breast Cancer
Location: Birmingham, AL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-35805
Conditions: Breast Cancer
Location: Huntsville, AL
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-37066
Conditions: Breast Cancer
Location: Gallatin, TN
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer - NCT00887536-37067
Conditions: Breast Cancer
Location: Franklin, TN
|
|